Publicaciones (92) Publicaciones en las que ha participado algún/a investigador/a

2014

  1. 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) disrupts blood-brain barrier integrity through a mechanism involving P2X7 receptors

    International Journal of Neuropsychopharmacology, Vol. 17, Núm. 8, pp. 1243-1255

  2. A restricted population of CB1 cannabinoid receptors with neuroprotective activity

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, Núm. 22, pp. 8257-8262

  3. A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis

    Angewandte Chemie - International Edition, Vol. 53, Núm. 50, pp. 13765-13770

  4. An update on dry eye disease molecular treatment: Advances in drug pipelines

    Expert Opinion on Pharmacotherapy, Vol. 15, Núm. 10, pp. 1371-1390

  5. Antioxidant and protective mechanisms against hypoxia and hypoglycaemia in cortical neurons in Vitro

    International Journal of Molecular Sciences, Vol. 15, Núm. 2, pp. 2475-2493

  6. Apoptosis-related proteins are potential markers of neonatal hypoxic-ischemic encephalopathy (HIE) injury

    Neuroscience Letters, Vol. 558, pp. 143-148

  7. Assessment of inner retina dysfunction and progressive ganglion cell loss in a mouse model of glaucoma

    Experimental Eye Research, Vol. 122, pp. 40-49

  8. Association of cigarette smoking and metabolic syndrome in a puerto rican adult population

    International Journal of Preventive Medicine, Vol. 5, Núm. 7, pp. 849-856

  9. Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis. A 2-year follow-up study

    Schizophrenia Research, Vol. 156, Núm. 1, pp. 23-29

  10. Birth weight, working memory and epigenetic signatures in IGF2 and related genes: A MZ twin study

    PLoS ONE, Vol. 9, Núm. 8

  11. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

    Epilepsia, Vol. 55, Núm. 6, pp. 791-802

  12. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 73, pp. 56-72

  13. Cannabinoid type 1 receptors transiently silence glutamatergic nerve terminals of cultured cerebellar granule cells

    PLoS ONE, Vol. 9, Núm. 2

  14. Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias

    British Journal of Pharmacology, Vol. 171, Núm. 6, pp. 1472-1489

  15. Changes in endocannabinoid receptors and enzymes in the spinal cord of sod1g93a transgenic mice and evaluation of a sativex®-like combination of phytocannabinoids: Interest for future therapies in amyotrophic lateral sclerosis

    CNS Neuroscience and Therapeutics, Vol. 20, Núm. 9, pp. 809-815

  16. Characterization of Gcf2/Lrrfip1 in experimental cerebral ischemia and its role as a modulator of Akt, mTOR and β-catenin signaling pathways

    Neuroscience, Vol. 268, pp. 48-65

  17. Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia

    Human Molecular Genetics, Vol. 23, Núm. 3, pp. 749-754

  18. Chronic melatonin treatment rescues electrophysiological and neuromorphological deficits in a mouse model of Down syndrome

    Journal of Pineal Research, Vol. 56, Núm. 1, pp. 51-61

  19. Combining rimonabant and fentanyl in a single entity: Preparation and pharmacological results

    Drug Design, Development and Therapy, Vol. 8, pp. 263-277

  20. Contribution of crk adaptor proteins to host cell and bacteria interactions

    BioMed Research International, Vol. 2014